Baseline Characteristics
emesis
Between November 24, 2020, and July 26, 2021, 211 patients were screened for eligibility. After the exclusion of 111 patients for ineligibility, the remaining 100 patients (mean [SD] age, 46.6 [10.9] years; 83 [83.0%] male) were randomly assigned to receive fosaprepitant weekly (50 patients) or every 3 weeks (50 patients) (eFigure 1 in Most patients (97 patients [97.0%]) completed all the treatment cycles, and only 3 patients discontinued (for reasons other than emesis) because of cancellation of cisplatin treatment due to a creatinine clearance of less than 60 mL/min/1.73 m